Vancouver, BC - August 11, 2016
- LED Medical Diagnostics Inc. ("LED Medical" or "the Company"), has announced the results of an oral health screening program in conjunction with London Drugs, a Canada-based pharmacy and retailer with 78 stores across British Columbia, Alberta, Saskatchewan and Manitoba. Following a successful pilot oral mucosal screening program in 2015, London Drugs again offered customers the opportunity to have a comprehensive oral examination to screen for oral mucosal abnormalities while incorporating tissue fluorescence visualization technology.
The screenings incorporate the use of LED Medical Diagnostics' VELscope® Vx Enhanced Oral Assessment System, a device utilized as an adjunct to the comprehensive oral examination, that enhances the ability of clinicians to visualize oral mucosal abnormalities that many not be apparent to the naked eye, including oral cancer, pre-malignant dysplasia and infections. The oral health screenings were conducted by Stacey-Rhodes Nessett, a Registered Dental Hygienist, and Dr. Ken Neuman, an accomplished dentist and member of the University of British Columbia Faculty of Dentistry.
As the sixth most prevalent cancer globally, oral cancer is often diagnosed in late stages, when the five- year survival rate is lower. Early detection and diagnosis of this disease through routine oral health screenings is often suggested as a means to finding the cancer in earlier stages where treatment is often more conservative with a better patient outcome.
The screenings were available between April 25th and May 18th at 14 London Drugs locations in and around the greater Vancouver, British Columbia market. Consumer demand for the screenings was very high, with waiting lists during several days of the event. Patients paid a fee of $25 per screening, with $5 of each examination being donated to the British Columbia Oral Cancer Prevention Program (BCOCPP).
Of the 167 patients screened, over 20% exhibited an oral mucosal abnormality that was discovered during the examination and were subsequently referred to a dental clinician for further diagnostic intervention.
Customers that received the oral health screenings were invited to complete a post-examination survey, providing invaluable feedback regarding their experience. 96% of those polled indicated that they would recommend a friend or family member to be screened and 86% of patients responded that they are committed to continuing on with yearly oral health screenings, whether through London Drugs or at their family dental practice. These statistics reinforce the need for expanding the performance of routine oral screenings, in both dental practices and in non-traditional outlets. London Drugs has already committed to another round of screening clinics tentatively scheduled for April 2017.
"We are beyond pleased to be able to provide this service to our customers and patients," stated John Tse, vice president, pharmacy, London Drugs. "Our customers' response to this screening program has been extremely positive with full clinic attendance. Because we know this oral screening education and availability at London Drugs is important to our customers and patients, we will continue to work together with our dental partners to provide this valuable service."
"What we see is that oral cancer, its risk factors, which include tobacco, alcohol and human papilloma virus (HPV), and the necessity for routine oral examinations needs improved awareness," stated Wayne Rees, vice president of VELscope Imaging for LED Dental. "Once made aware of the importance of screening to their overall health, many patients will choose and pay for these services, whether provided by businesses such as London Drugs or through their dental provider."
"We are proud to partner with London Drugs to improve access of oral screenings utilizing VELscope technology to the general public," concluded Dr. David Gane, CEO of LED Medical Diagnostics. "The use of the VELscope as an additional tool during these examinations gives confidence to patients, knowing that their oral healthcare provider is relying on the latest tissue fluorescence visualization technology as a safeguard against overlooking oral abnormalities that may not be visible to the naked eye."
For more information on the VELscope, please visit www.velscope.com
. For information on London Drugs and their oral health screening program, please visit www.londondrugs.com
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Vancouver, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.
The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, call 844.952.7327 or visit www.leddental.com/investor-relations
About London Drugs
Founded in 1945, B.C.-based London Drugs has 79 stores in more than 35 major markets throughout British Columbia, Alberta, Saskatchewan and Manitoba including its online store www.londondrugs.com. London Drugs offers consumers a range of products from digital cameras and cosmetics to computers and televisions. Renowned for its creative approach to retailing, the company employs more than 7,500 people with pharmacy and health care services being the heart of its business. Committed to innovation and superior customer service, London Drugs has established itself as a reputable and caring company and continues to position itself for future growth and development. @LondonDrugs
LED Medical Diagnostics
Phone: 905.326.1888, ext. 10
David Gane, CEO
Phone: 604-434-4614 x227
Forward Looking Statement
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2015. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.